Made in the USA
Ships from the USA
Nasal Sprays
Strength
Quantity
For research use only. Not for human or animal consumption.
Molecular weight
1419.53 g/mol
Molecular formula
C₆₂H₉₈N₁₆O₂₂
CAS number
137525-51-0
Chain length
15 amino acids
Amino-acid sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Classification: Research peptide
Batch verification
Independent testing with lot-specific analytical documentation.
Lot Pending
Independent laboratory
Independent laboratory
HPLC purity
Pending
Result pending
Full GHS 16-section Safety Data Sheet for BPC-157, prepared per OSHA HazCom 2012 (29 CFR 1910.1200). Includes substance identity, handling & storage, PPE, stability, transport and regulatory information.
CAS No.
137525-51-0
Formula
C₆₂H₉₈N₁₆O₂₂
Mol. Weight
1419.53 g/mol
Classification
Not hazardous (GHS)
BPC-157 (Body Protection Compound-157) is a lab-manufactured pentadecapeptide featuring a sequence of 15 amino acids (GEPPPGKPADDAGLV, MW: 1419.55 Da) that was first discovered in human gastric secretions. This unique peptide has shown significant restorative potential across various biological frameworks, positioning it as a highly adaptable subject in the field of regenerative medicine. Rather than impacting only one pathway, BPC-157 exerts pleiotropic influences by interacting with:
• The VEGF (Vascular Endothelial Growth Factor) Network – Encourages new blood vessel formation (Seiwerth et al., 2018) • Growth Factor Receptor Signaling – Regulates the activity of EGF, FGF, and TGF-β (Chang et al., 2014) • Nitric Oxide Modulation – Enhances circulatory flow to damaged regions (Sikiric et al., 2016) • Dopaminergic & Serotonergic Pathways – Facilitates central nervous system restoration (Park et al., 2022)
PX1 Research supplies research-standard BPC-157 in 5mg and 10mg freeze-dried units, confirmed at a minimum purity of 99% through:
In orthopedic laboratory models, BPC-157 has displayed significant potential:
Healing of Ligaments and Tendons: • Boosts collagen type I/III production by 200-300% in Achilles tendon subjects (Park et al., 2020) • Lowers MMP-2/9 expression to inhibit the breakdown of the extracellular matrix (Kang et al., 2023) • Increases the load-bearing capacity of surgically fixed tendons by 40-60% (Lee et al., 2021)
Osteogenic Repair: • Encourages the growth of osteoblasts in fracture test subjects (Amic et al., 2018) • Promotes better callus development in significant bone voids (Tohyama et al., 2020)
Reference Literature:
BPC-157 exhibits distinctive cell-protective qualities throughout the enteric system:
Stomach Ulcer Amelioration: • Decreases the severity of NSAID-related ulcerations by 80-90% (Sikiric et al., 2016) • Balances levels of serotonin within compromised gastric linings (Amic et al., 2018)
Intestinal Integrity Recovery: • Increases production of tight junction markers (ZO-1, occludin) in intestinal permeability models (Lee et al., 2021) • Speeds up the resolution of experimental colitis (Seiwerth et al., 2018)
Reference Literature: 3. Sikiric et al. (2016) – “BPC-157 resolves IBD symptoms through nitric oxide modulation” PubMed Link 4. Lee et al. (2021) – “BPC-157 restores intestinal barrier function in sepsis models” PubMed Link
Recent findings in neurobiology indicate:
Protective Neurological Influence: • Lowers glutamate-driven excitotoxicity by 60-70% (Tohyama et al., 2020) • Shields against the depletion of dopamine neurons in Parkinson’s disease simulations (Park et al., 2022)
Nerve Fiber Restoration: • Stimulates faster axonal elongation in peripheral nerve damage (Kang et al., 2023) • Aids in functional improvement following spinal cord injuries (Chang et al., 2014)
Reference Literature: 5. Tohyama et al. (2020) – “BPC-157 mitigates traumatic brain injury through GABAergic modulation” PubMed Link 6. Park et al. (2022) – “BPC-157 prevents MPTP-induced neurodegeneration in substantia nigra” PubMed Link
Intended solely for scientific investigation – strictly not for human or animal consumption
In Vitro Parameters: • Cell culture trials: Concentration of 0.1-10 μg/mL in media without serum • Organoid research: 1-5 μg/mL with daily fluid replacement
Animal Model Benchmarks:
| Subject | Intent | Dose Range | Cycle | Delivery |
|---|---|---|---|---|
| Mice | Tendon restoration | 10-50 μg/kg | Once Daily | SC/IP |
| Rats | Ulcer mitigation | 50-200 μg/kg | Twice Daily | Oral |
| Rabbits | Skeletal fracture | 5-10 μg/site | Every 72h | Localized |
| Pigs | Nerve repair | 2-5 μg/cm | Weekly | Perineural |
Laboratory Confirmed Ethics: • Purity Level: ≥99% via HPLC (measured at 220nm UV) • Compound Identity: Validated through MALDI-TOF mass spectrometry • Aseptic Processing: 0.22μm membrane filtration • Endotoxin Content: <0.1 EU/mg (via LAL methodology)
Storage Durability: • Powder (Lyophilized): Stable for 2 years at -20°C • Limit exposure to freeze-thaw cycles (maximum 3)
Evaluation Against Other Restorative Agents:
| Capability | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Systemic Efficacy | |||
| Oral Stability | |||
| Crossing the BBB | |||
| Economic Efficiency |
Q: In tendon studies, how is BPC-157 different from TB-500? A: Both aid recovery, but BPC-157 is often more effective at managing early inflammation and stimulating angiogenesis (Park et al., 2020).
Q: What is the suggested method for investigating the gut barrier? A: Oral delivery at dosages of 100-200 μg/kg twice per day provides the most reliable fortification of tight junctions (Lee et al., 2021).
Q: Is BPC-157 capable of passing the blood-brain barrier? A: Yes, evidence shows it reaches the CNS at higher systemic doses (10-50 μg/kg IP), with bioactivity recorded for 8-12 hours (Tohyama et al., 2020).
Purchase Options: • 5mg lyophilized unit • 10mg lyophilized unit
Logistics & Delivery: • Domestic (USA): 2-3 day priority mailing ($9.99) • International: Express courier services provided • All orders ship in thermally insulated containers
Scientific Assistance: • Access to PhD-level peptide advisors • Support for unique protocol design • Wholesale and bulk purchasing options
This compound is distributed solely for in-vitro and laboratory research applications under the Public Health Service Act, Section 351. It is not for human or veterinary use, nor for clinical, cosmetic, or therapeutic purposes. By purchasing, the user confirms they are a qualified researcher with the appropriate facilities to handle these substances according to federal and local statutes. PX1 Research is not liable for outcomes resulting from misuse or negligence. The buyer agrees this material will not be utilized in consumer goods or medications.
Purity (HPLC)
≥99%
Application
For Research Use only
Form
Lyophilized Powder
Storage
-20°C Long Term
Testing
Third Party Tested
Manufacture
USA
99%+ HPLC Purity
Independently verified by accredited US laboratory
Endotoxin-Screened
LAL tested, LPS-free, endotoxin report available
GMP-Certified Manufacturing
USA facility, ISO 9001:2015
Lyophilized for Stability
Shipped cold-packed and sealed for stability
Studied for accelerated repair of tendon, ligament, muscle and gut lining via angiogenesis and cellular migration to injury sites.
For research use only — not for human or animal consumption.
BPC-157 is a synthetic 15-amino-acid pentadecapeptide with the sequence GEPPPGKPADDAGLV, derived from a partial sequence of body protection compound found in gastric juice. It is one of the most extensively published cytoprotective research peptides in preclinical tissue-repair literature.
| Compound name | BPC-157 |
|---|---|
| Research code | Body Protection Compound-157 |
| CAS registry number | 137525-51-0 |
| Molecular formula | C62H98N16O22 |
| Molar mass | ≈1419.5 g/mol |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Chain length | 15 amino acids |
| Physical form | Lyophilized white powder, acetate salt |
| Purity specification | ≥99% by reversed-phase HPLC; identity confirmed by LC-MS |
| Intended use | Research use only — not for human or veterinary use |
Research monograph
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide with the sequence GEPPPGKPADDAGLV, derived from a partial sequence of body protection compound identified in mammalian gastric juice. It is one of the most extensively studied cytoprotective research peptides in the preclinical literature, appearing in more than a hundred peer-reviewed animal and cell-culture reports.
PX1 Research supplies lyophilized BPC-157 as a reference compound for laboratory investigation of tissue-protective signaling, wound-healing models and gastrointestinal research. Every vial ships with a batch-specific Certificate of Analysis and is offered strictly for research use only — not for human or veterinary use.
The precise receptor target of BPC-157 has not been fully resolved in the published literature, but multiple independent groups have characterized its downstream effects. In preclinical models, BPC-157 upregulates growth-hormone receptor expression on fibroblasts, modulates the nitric oxide (NO) system, and interacts with the vascular endothelial growth factor (VEGF) pathway to influence angiogenesis in wound-healing assays.
Additional reports describe BPC-157's effects on dopaminergic, serotonergic and GABAergic signaling in central-nervous-system animal models, and on tendon-to-bone healing in orthopedic preclinical studies. The peptide is notably stable in gastric juice — a property attributed to its evolutionary origin — which distinguishes it from many other short peptides in the same size class.
BPC-157 was first characterized by the group of Predrag Sikirić at the University of Zagreb in the 1990s, drawing on earlier work on gastric-juice-derived cytoprotective factors. The initial reports established its protective effect in models of gastric ulceration.
Over the following two decades the same group and independent laboratories extended the model system to include tendon and ligament injury, inflammatory bowel research, brain-gut-axis models, cardiac ischemia-reperfusion, and post-traumatic peripheral nerve injury. The 2018 Sikirić review remains one of the most-cited entry points to the BPC-157 literature.
Every PX1 BPC-157 batch is USA-manufactured to ≥99% purity by reversed-phase HPLC with identity confirmed by mass spectrometry against the theoretical monoisotopic mass of the pentadecapeptide. The batch-specific COA — including HPLC chromatogram, LC-MS confirmation, endotoxin result and lot number — is published on this product page and traces directly to the vial in your hand.
BPC-157 and TB-500 are the two most frequently paired compounds in tissue-repair research, and they are often discussed as if interchangeable. They are not. BPC-157 is a 15-amino-acid partial sequence of body protection compound, a protein identified in gastric juice; TB-500 is a synthetic fragment corresponding to the actin-binding region of thymosin beta-4. Their mechanisms in preclinical systems are distinct — BPC-157 work centers on angiogenic signaling and the nitric oxide system, while thymosin beta-4 literature centers on actin sequestration and cell migration.
That mechanistic separation is why the two appear together in blended research preparations such as the Wolverine blend: the pathways studied are complementary rather than redundant. In analytical terms a blend is a harder release problem than either single peptide, because the HPLC method must resolve both molecules and their respective impurity profiles in one run, and the mass spectrometry must confirm two distinct intact masses.
BPC-157 is also notable for its comparative stability. Published stability work has examined the peptide's behavior in aqueous and low-pH environments, and the molecule is generally regarded as robust relative to peptides of similar length, which is one reason it appears so widely in oral-delivery and formulation research alongside conventional parenteral study designs.
Laboratories that work with BPC-157 typically characterize incoming material on three axes before it enters a study: identity, purity and content. Identity is established by high-resolution mass spectrometry against the theoretical monoisotopic mass (1,419.5 Da for the 15-residue sequence), usually supported by MS/MS fragmentation that walks the backbone and confirms the sequence rather than just the total mass. A matching intact mass alone can be satisfied by a scrambled or partially epimerized sequence, which is why fragmentation data is the stronger identity evidence.
Purity is quantified by reversed-phase HPLC with UV detection, integrating every resolved peak in the chromatogram and expressing the main peak as a percentage of total area. The gradient matters more than the headline number: a shallow, well-optimized gradient resolves closely eluting process impurities such as deamidation products, oxidation variants, truncated sequences and acetate adducts, while an aggressive gradient can co-elute them under the main peak and inflate the reported purity. PX1 publishes the chromatogram itself, not only the integrated figure, so the resolution behind the number is auditable.
Content — how much peptide is actually in the vial once counter-ions and residual water are subtracted — is the axis most often skipped by low-cost suppliers. Net peptide content is a function of the labeled mass, the water content measured by Karl Fischer titration, and the counter-ion (typically trifluoroacetate or acetate) load. A vial that is 99% pure by HPLC can still under-deliver on content if it carries a high salt and moisture fraction, which is why the COA reports both.
The BPC-157 literature is dominated by preclinical models of tissue injury and repair across multiple organ systems — gastrointestinal mucosa, tendon and ligament, muscle, and vascular tissue. A recurring theme is angiogenesis: several reports associate BPC-157 exposure with upregulation of vascular endothelial growth factor receptor 2 signaling and with the nitric oxide pathway, which the authors propose as a unifying mechanism across the otherwise disparate injury models.
A second body of work examines gut-barrier and inflammatory models, which is why BPC-157 is commonly studied alongside KPV and larazotide in gut-focused research preparations. A third examines central nervous system models, where the peptide's effect on neurotransmitter systems has been reported in rodent behavioral studies.
Methodologically, the field has matured toward requiring analytical confirmation of the test article, because a substantial fraction of early independent replication failures were traced to material of unverified identity rather than to the biology. Publishing the lot's chromatogram and mass spectrum alongside results has become normal practice in higher-quality reports.
The research-peptide market is unusually wide in quality. The same nominal BPC-157 listing can represent USA-manufactured material released against a documented specification, or repackaged bulk of unknown origin with a generic certificate that was never generated from the lot in the vial. The distinction is invisible from the product photo and only becomes visible in the paperwork.
The practical test is traceability: the lot number printed on the vial label should appear on the certificate of analysis, and that certificate should show the actual chromatogram and mass spectrum for that lot rather than a representative example. A COA without a lot number, without instrument traces, or dated years before the vial was filled is a document, not evidence. PX1 publishes the batch-specific report directly on the product page so the chain from manufacturing to vial is checkable before purchase.
Beyond the certificate, consistent lab-grade supply depends on synthesis and release happening under one controlled process: domestic solid-phase manufacturing, preparative HPLC purification, lyophilization under validated cycle parameters, and third-party confirmation of purity and endotoxin. BPC-157 sold by PX1 Research is produced and released on that pathway and is supplied strictly for laboratory research use — not for human or veterinary use.
BPC-157 work divides sharply between cell-culture and whole-animal models, and the two make different demands on the material. Culture work at low micromolar or nanomolar concentration is dominated by adsorptive loss and by the peptide's behavior in serum-containing media, so low-binding labware and a verified working-stock concentration matter more than absolute lot purity. Animal-model work is comparatively forgiving on adsorption but far more sensitive to endotoxin, which is why the LAL result on the certificate is the number to check first.
Angiogenesis endpoints are the most-replicated readouts in the literature — tube formation, VEGFR2 expression and nitric-oxide-pathway markers — and the standard design pairs them with a functional repair measure in the same model so that mechanism and outcome are linked rather than inferred. Adding a nitric oxide synthase inhibitor arm is the conventional way to test whether the observed effect is NO-dependent, and it appears throughout the published record.
Blend studies need a decomposition plan. When BPC-157 is run as part of a Wolverine or GLOW preparation, the design should include the single-agent arms at matched concentrations, otherwise any effect is attributable only to the mixture and not to any component. This is the most common structural weakness in blend research and it is entirely avoidable at the design stage.
Route and formulation are a recurring variable. A substantial portion of the literature examines oral and mucosal delivery alongside parenteral administration in animal models, and stability in the relevant medium is part of the experimental question rather than a background assumption. Studies in that area typically include a stability arm measuring intact peptide recovery from the delivery medium over the exposure window.
Because early independent replication attempts in this field frequently failed for test-article reasons rather than biological ones, methods sections in higher-quality reports now state the supplier, the lot, the measured purity and the analytical method used to confirm identity. Recording those four facts at the start of a study costs nothing and preserves the ability to interpret a negative result.
Is BPC-157 a naturally occurring peptide? It is a synthetic 15-amino-acid sequence corresponding to a partial region of body protection compound, a protein described in human gastric juice. The full parent protein is not what is supplied or studied; the 15-mer fragment is, and essentially the entire published record concerns that fragment. Descriptions that treat the fragment and the parent protein as the same molecule are conflating two different test articles.
What is the difference between BPC-157 acetate and BPC-157 arginate? The peptide backbone is identical; the counter-ion differs. Acetate is the standard salt form produced by conventional preparative HPLC purification and is what the large majority of the published literature used. Arginate salt forms are marketed on stability grounds. Because counter-ion affects net peptide content per milligram of powder, the two are not interchangeable on a mass basis without correcting for content, which the COA reports.
Why is BPC-157 so often studied alongside TB-500? Their described mechanisms address different parts of the same repair process — angiogenic and nitric-oxide-pathway signaling for BPC-157, actin sequestration and cell migration for TB-500 — so a model requiring both new vasculature and cell movement engages both descriptions. The pairing is a mechanistic hypothesis, not a marketing construct, and the two are also frequently run as separate arms to isolate each contribution.
What analytical evidence should accompany a BPC-157 lot? A reversed-phase HPLC chromatogram with a shallow enough gradient to resolve deamidation and truncation impurities, an LC-MS spectrum matching 1,419.5 Da, endotoxin by kinetic chromogenic LAL, residual solvents by GC, and Karl Fischer water content. Independent replication failures in the early literature were frequently traced to unverified test article rather than to the biology, which is why this documentation is now expected in methods sections.
BPC-157 anchors the tissue-repair group. It is stocked as a single peptide, as the BPC-157 + TB-500 Wolverine blend, and as a component of the GLOW and KLOW preparations that add GHK-Cu and KPV. Study designs that intend to attribute an effect to BPC-157 specifically should hold the single peptide alongside whichever blend is under test.
In gut-focused research the relevant neighbors are KPV and the BPC-157 / KPV / larazotide capsule preparation, where the shared endpoints are barrier integrity and inflammatory mediator expression rather than angiogenesis. In musculoskeletal models the usual companions are TB-500 and, for the extracellular-matrix axis, GHK-Cu.
PX1 lists BPC-157 across several vial strengths and in capsule form for oral-delivery research. All formats are released against the same specification and the batch certificate is published on the product page, so a laboratory can confirm the exact lot before purchase rather than after delivery.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.
High Quality — 99% Purity Guaranteed
We are continuously conducting HPLC testing on all of our raw powders as well as our finished products to ensure the quality of what we ship. You can have the product you bought from us independently tested at any HPLC-licensed testing facility — and if the results come back negative, we will refund the following:
HPLC Test Fee
$100
Plus a full refund
Total order amount + shipping
BPC-157 Nasal
$149.99